Free CME from PeerView


Continuing Nursing Education (CNE) Activities

Credits: 1.0 CME / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?

Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?

Start

Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?

Media: Enduring Material
Activity Release Date: November 15, 2022
Activity Expiration Date: November 14, 2023
Time to Complete Activity: 60 minutes

Activity Description

This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educational modules, learners will combine self-assessment with concise clinical content in an interactive format. An expert GU oncologist presents digestible self-study segments, with a particular focus on CV considerations associated with ADT approaches. Explore topics pertinent to effective management of patients with prostate cancer on ADT regimens in your clinical practice and learn more about the impact of CV considerations and team-based models of care.

Target Audience

This activity has been designed to meet the educational needs of the key care team clinicians in the best position to positively impact safety, survival, and QoL outcomes of patients with advanced PC who require ADT, including urologists, medical oncologists, radiation oncologists, nurse practitioners (NPs), physician assistants (PAs), pharmacists, and other allied healthcare professionals.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Differentiate between GnRH analogues (agonists or antagonists) for patients with advanced prostate cancer with respect to their mechanism of action, clinical effects, cardiovascular (CV) safety, and other attributes
  • Select patients with advanced prostate cancer who may benefit from treatment with a GnRH antagonist based on CV risk, comorbidities, patient preferences (eg, regarding dosing and/or administration route), and other individualized factors
  • Collaborate with multidisciplinary and interprofessional care colleagues to appropriately assess and manage CV risk in patients with advanced prostate cancer who require ADT

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Daniel J. George, MD
Professor of Medicine and Surgery
Divisions of Medical Oncology and Urology
Duke University Medical Center
Co-Lead, DCI Center for Prostate and Urologic Cancers
Duke Cancer Institute
Durham, North Carolina

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

Funding for this Independent Medical Education Activity is provided from Pfizer Inc and Myovant Sciences Ltd.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-050-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes?

Media: Enduring Material
Activity Release Date: November 15, 2022
Activity Expiration Date: November 14, 2023
Time to Complete Activity: 60 minutes

Activity Description

This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educational modules, learners will combine self-assessment with concise clinical content in an interactive format. An expert GU oncologist presents digestible self-study segments, with a particular focus on CV considerations associated with ADT approaches. Explore topics pertinent to effective management of patients with prostate cancer on ADT regimens in your clinical practice and learn more about the impact of CV considerations and team-based models of care.

Target Audience

This activity has been designed to meet the educational needs of the key care team clinicians in the best position to positively impact safety, survival, and QoL outcomes of patients with advanced PC who require ADT, including urologists, medical oncologists, radiation oncologists, nurse practitioners (NPs), physician assistants (PAs), pharmacists, and other allied healthcare professionals.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Differentiate between GnRH analogues (agonists or antagonists) for patients with advanced prostate cancer with respect to their mechanism of action, clinical effects, cardiovascular (CV) safety, and other attributes
  • Select patients with advanced prostate cancer who may benefit from treatment with a GnRH antagonist based on CV risk, comorbidities, patient preferences (eg, regarding dosing and/or administration route), and other individualized factors
  • Collaborate with multidisciplinary and interprofessional care colleagues to appropriately assess and manage CV risk in patients with advanced prostate cancer who require ADT

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Daniel J. George, MD
Professor of Medicine and Surgery
Divisions of Medical Oncology and Urology
Duke University Medical Center
Co-Lead, DCI Center for Prostate and Urologic Cancers
Duke Cancer Institute
Durham, North Carolina

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

Funding for this Independent Medical Education Activity is provided from Pfizer Inc and Myovant Sciences Ltd.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-050-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

November 15, 2022
Credits: 0.75 CME / MOC / NCPD / IPCE
PVI, PeerView Institute for Medical Education
Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates

Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates

Start

Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates

Media: Enduring Material
Activity Release Date: October 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 45 minutes

Activity Description

Metastatic urothelial carcinoma (UC) is a devastating illness with limited treatment options, especially for patients who have been previously treated with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. The activity also features a patient and his caregiver’s perspective on their first-hand experience with the treatment strategies and his journey.
These experts review the latest data and ongoing research on platinum-based chemotherapy, antibody–drug conjugates, and pan-FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics.

Target Audience

This activity has been designed to meet the educational needs of oncologists, advanced practice oncology clinicians (NPs and PAs), oncology nurses, and other interprofessional cancer care team members who manage patients with urothelial carcinoma (UC)

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Integrate novel antibody-drug conjugates (ADCs) into individualized management plans for appropriate patients with metastatic UC, taking into consideration treatment history, latest clinical evidence, and current guideline recommendations
  • Implement team-based strategies to monitor for and manage treatment-related adverse events that may occur in patients with metastatic UC who are receiving novel ADCs as part of their care
  • Apply an interprofessional team-based approach to care for patients with metastatic UC that incorporates shared decision-making, appropriate patient education and counseling, and effective interprofessional collaboration and care coordination

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Scott T. Tagawa, MD, MS, FACP
Professor of Medicine & Urology
Meyer Cancer Center
Weill Cornell Medicine
New York, New York

Scott T. Tagawa, MD, MS, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AAA/Novartis Pharmaceuticals Corporation; AbbVie Inc.; AIkido Pharma Inc.; Amgen Inc.; Astellas Pharma US, Inc.; Bayer Corporation; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics, Inc.; Dendreon Pharmaceuticals LLC; EMD Serono, Inc.; Eisai Inc.; Endocyte; Genentech, Inc.; Genomic Health, Inc.; Immunomedics, Inc.; Janssen Pharmaceuticals, Inc.; Karyopharm; Medivation, Inc.; Myovant Sciences Ltd.; Pfizer; POINT Biopharma Global Inc.; QED Therapeutics, Inc.; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; Telix Pharmaceuticals Limited; and Tolmar Pharmaceuticals, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; ATLAB Pharma; AVEO Pharmaceuticals, Inc.; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Dendreon Pharmaceuticals LLC; Endocyte; Genentech, Inc.; Gilead Sciences, Inc.; Immunomedics, Inc.; INOVIO Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Karyopharm; Lilly; Medivation, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc; NewLink Genetics; Novartis Pharmaceuticals Corporation; POINT Biopharma Global Inc.; Progenics Pharmaceuticals, Inc.; Rexahn Pharmaceuticals; sanofi-aventis U.S. LLC; and Seattle Genetics, Inc.
Stock Shareholder in AIkido Pharma Inc.
Other Financial or Material Support Patent for Gilead Sciences, Inc.; Immunomedics, Inc.; and Weill Medical College.

Faculty/Planner
Amie Patel, RN, BSN, MS, CCRC
Research Nurse Specialist
Genitourinary Oncology
Meyer Cancer Center
Weill Cornell Medical Center
New York Presbyterian Hospital
New York, New York

Amie Patel, RN, BSN, MS, CCRC, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Rosario Ardizzone

Rosario Ardizzone has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates

Media: Enduring Material
Activity Release Date: October 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 45 minutes

Activity Description

Metastatic urothelial carcinoma (UC) is a devastating illness with limited treatment options, especially for patients who have been previously treated with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. The activity also features a patient and his caregiver’s perspective on their first-hand experience with the treatment strategies and his journey.
These experts review the latest data and ongoing research on platinum-based chemotherapy, antibody–drug conjugates, and pan-FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics.

Target Audience

This activity has been designed to meet the educational needs of oncologists, advanced practice oncology clinicians (NPs and PAs), oncology nurses, and other interprofessional cancer care team members who manage patients with urothelial carcinoma (UC)

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Integrate novel antibody-drug conjugates (ADCs) into individualized management plans for appropriate patients with metastatic UC, taking into consideration treatment history, latest clinical evidence, and current guideline recommendations
  • Implement team-based strategies to monitor for and manage treatment-related adverse events that may occur in patients with metastatic UC who are receiving novel ADCs as part of their care
  • Apply an interprofessional team-based approach to care for patients with metastatic UC that incorporates shared decision-making, appropriate patient education and counseling, and effective interprofessional collaboration and care coordination

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Scott T. Tagawa, MD, MS, FACP
Professor of Medicine & Urology
Meyer Cancer Center
Weill Cornell Medicine
New York, New York

Scott T. Tagawa, MD, MS, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AAA/Novartis Pharmaceuticals Corporation; AbbVie Inc.; AIkido Pharma Inc.; Amgen Inc.; Astellas Pharma US, Inc.; Bayer Corporation; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics, Inc.; Dendreon Pharmaceuticals LLC; EMD Serono, Inc.; Eisai Inc.; Endocyte; Genentech, Inc.; Genomic Health, Inc.; Immunomedics, Inc.; Janssen Pharmaceuticals, Inc.; Karyopharm; Medivation, Inc.; Myovant Sciences Ltd.; Pfizer; POINT Biopharma Global Inc.; QED Therapeutics, Inc.; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; Telix Pharmaceuticals Limited; and Tolmar Pharmaceuticals, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; ATLAB Pharma; AVEO Pharmaceuticals, Inc.; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Dendreon Pharmaceuticals LLC; Endocyte; Genentech, Inc.; Gilead Sciences, Inc.; Immunomedics, Inc.; INOVIO Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Karyopharm; Lilly; Medivation, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc; NewLink Genetics; Novartis Pharmaceuticals Corporation; POINT Biopharma Global Inc.; Progenics Pharmaceuticals, Inc.; Rexahn Pharmaceuticals; sanofi-aventis U.S. LLC; and Seattle Genetics, Inc.
Stock Shareholder in AIkido Pharma Inc.
Other Financial or Material Support Patent for Gilead Sciences, Inc.; Immunomedics, Inc.; and Weill Medical College.

Faculty/Planner
Amie Patel, RN, BSN, MS, CCRC
Research Nurse Specialist
Genitourinary Oncology
Meyer Cancer Center
Weill Cornell Medical Center
New York Presbyterian Hospital
New York, New York

Amie Patel, RN, BSN, MS, CCRC, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Rosario Ardizzone

Rosario Ardizzone has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

October 27, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
Heart Failure Society of America
Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

Start

Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

Activity Description

How are you pushing back against HCM in your practice? In PeerView’s latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM
  • Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner
  • Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM
  • Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management

Target Audience

This activity has been designed to meet the educational needs of heart failure specialists, cardiovascular surgeons, general cardiologists, internal medicine physicians, family physicians, advanced practice clinicians (NPs/PAs), nurses, pharmacists, and other healthcare professionals involved in the management of HCM.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 21, 2022 - November 20, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

It is the policy of HFSA to ensure balance, independence, objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).

All individuals who serve as faculty, are on a committee, or are in a position to influence the content of a certified CE activity must disclose any relevant financial relationship that might affect the independent, unbiased development and presentation of the CE content.

Chair & Presenter
Milind Desai, MD, MBA
Haslam Family Endowed Chair in CV Medicine
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Director, Clinical Operations
Director, HCM Center
Department of Cardiovascular Medicine
Heart and Vascular Institute
Cleveland, Ohio

Milind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; and Medtronic.

Presenter
Neal K. Lakdawala, MD
Cardiovascular Genetics, Heart Failure and Cardiac Transplantation
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Neal K. Lakdawala, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; Sarepta Therapeutics, Inc.; and Tenaya Therapeutics.

Presenter
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; and Renovacor, Inc.

Planner
Margery Tamas, MPH
PVI, PeerView Institute for Medical Education

Margery Tamas, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for Fresenius Medical Care North America.

Accreditation, Credit, and Support


 

JAP In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Learners should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 1.0 MOC contact hour(s) in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Nurses

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum 1.0 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

ACPE The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.0 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-22-016-H04-P.

Reciprocity

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Off-Label Disclosure

This educational activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this educational activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and The Heart Failure Society of America are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this accredited CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Heart Failure Society of America.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

Activity Description

How are you pushing back against HCM in your practice? In PeerView’s latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM
  • Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner
  • Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM
  • Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management

Target Audience

This activity has been designed to meet the educational needs of heart failure specialists, cardiovascular surgeons, general cardiologists, internal medicine physicians, family physicians, advanced practice clinicians (NPs/PAs), nurses, pharmacists, and other healthcare professionals involved in the management of HCM.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 21, 2022 - November 20, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

It is the policy of HFSA to ensure balance, independence, objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).

All individuals who serve as faculty, are on a committee, or are in a position to influence the content of a certified CE activity must disclose any relevant financial relationship that might affect the independent, unbiased development and presentation of the CE content.

Chair & Presenter
Milind Desai, MD, MBA
Haslam Family Endowed Chair in CV Medicine
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Director, Clinical Operations
Director, HCM Center
Department of Cardiovascular Medicine
Heart and Vascular Institute
Cleveland, Ohio

Milind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; and Medtronic.

Presenter
Neal K. Lakdawala, MD
Cardiovascular Genetics, Heart Failure and Cardiac Transplantation
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Neal K. Lakdawala, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; Sarepta Therapeutics, Inc.; and Tenaya Therapeutics.

Presenter
Anjali Tiku Owens, MD
Director, Center for Inherited Cardiovascular Disease
Section of Heart Failure
Transplantation and Mechanical Circulatory Support
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Pfizer; and Renovacor, Inc.

Planner
Margery Tamas, MPH
PVI, PeerView Institute for Medical Education

Margery Tamas, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for Fresenius Medical Care North America.

Accreditation, Credit, and Support


 

JAP In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Learners should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC The Heart Failure Society of America designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 1.0 MOC contact hour(s) in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Nurses

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum 1.0 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

ACPE The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.0 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-22-016-H04-P.

Reciprocity

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Off-Label Disclosure

This educational activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this educational activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and The Heart Failure Society of America are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this accredited CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Heart Failure Society of America.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

October 21, 2022
Credits: 1.0 CME / MOC / NCPD
PVI, PeerView Institute for Medical Education
Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer

Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer

Start
CME Information - 150207871-1

CME/MOC/NCPD/IPCE Information Content

Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer

Media: Enduring Material
Activity Release Date: October 17, 2022
Activity Expiration Date: October 16, 2023
Time to Complete Activity: 60 minutes

Activity Description

Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on prescribed therapy by providing patient education, guidance, and appropriately monitoring and managing treatment-related adverse events.

Target Audience

This activity has been designed to meet the educational needs of oncologists, oncology staff nurses, advanced practice nurses, nurse navigators, and other care team professionals who manage patients with HR+/HER2- early breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Review the mechanism of action, latest safety and efficacy data, and clinical role of currently approved CDK4/6 inhibitors in HR+/HER2- early breast cancer
  • Describe disease-, treatment-, management-, patient-related, and other relevant factors that can impact adherence and persistence to oral therapies among patients with HR+/HER2- early breast cancer, including patient perceptions and education, adverse events, care coordination, and collaboration
  • Apply appropriate strategies to identify, treat, and monitor patients with HR+/HER2- early breast cancer receiving oral CDK4/6 inhibitor therapies to prevent/manage treatment- related adverse events (TRAEs)
  • Integrate effective team-based communication approaches, including shared decision- making, to appropriately educate and engage patients on CDK4/6 inhibitors about TRAEs, collaboratively establish and achieve treatment goals, and maximize adherence and persistence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women’s Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ARC Therapeutics; AstraZeneca; Athenex, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; Certara, USA; Chugai Pharmaceutical Co., Ltd.; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; Eisai Inc.; Ellipses Pharma; 4D pharma; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Infinity Therapeutics; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Odonate Therapeutics, Inc; OncoSec Medical Incorporated; OncXerna Therapeutics, Inc.; Pfizer; Reveal Genomics; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; Zentalis; and Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; sanofi-aventis U.S. LLC; and Seattle Genetics, Inc.

Co-Chair/Planner
Elahe Salehi, DNP, ANP-BC
Breast Oncology Center
Dana-Farber Cancer Institute
Director of Advanced Practice Nursing
Division of Women’s Cancers
Boston, Massachusetts

Elahe Salehi, DNP, ANP-BC, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

CME Information - 150207871-1

CME/MOC/NCPD/IPCE Information Content

Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer

Media: Enduring Material
Activity Release Date: October 17, 2022
Activity Expiration Date: October 16, 2023
Time to Complete Activity: 60 minutes

Activity Description

Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on prescribed therapy by providing patient education, guidance, and appropriately monitoring and managing treatment-related adverse events.

Target Audience

This activity has been designed to meet the educational needs of oncologists, oncology staff nurses, advanced practice nurses, nurse navigators, and other care team professionals who manage patients with HR+/HER2- early breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Review the mechanism of action, latest safety and efficacy data, and clinical role of currently approved CDK4/6 inhibitors in HR+/HER2- early breast cancer
  • Describe disease-, treatment-, management-, patient-related, and other relevant factors that can impact adherence and persistence to oral therapies among patients with HR+/HER2- early breast cancer, including patient perceptions and education, adverse events, care coordination, and collaboration
  • Apply appropriate strategies to identify, treat, and monitor patients with HR+/HER2- early breast cancer receiving oral CDK4/6 inhibitor therapies to prevent/manage treatment- related adverse events (TRAEs)
  • Integrate effective team-based communication approaches, including shared decision- making, to appropriately educate and engage patients on CDK4/6 inhibitors about TRAEs, collaboratively establish and achieve treatment goals, and maximize adherence and persistence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women’s Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ARC Therapeutics; AstraZeneca; Athenex, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; Certara, USA; Chugai Pharmaceutical Co., Ltd.; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; Eisai Inc.; Ellipses Pharma; 4D pharma; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Infinity Therapeutics; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Odonate Therapeutics, Inc; OncoSec Medical Incorporated; OncXerna Therapeutics, Inc.; Pfizer; Reveal Genomics; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; Zentalis; and Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; sanofi-aventis U.S. LLC; and Seattle Genetics, Inc.

Co-Chair/Planner
Elahe Salehi, DNP, ANP-BC
Breast Oncology Center
Dana-Farber Cancer Institute
Director of Advanced Practice Nursing
Division of Women’s Cancers
Boston, Massachusetts

Elahe Salehi, DNP, ANP-BC, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

October 17, 2022
Credits: 1.0 CME / MOC / NCPD
PVI, PeerView Institute for Medical Education
Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care

Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care

Start

Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care

Media: Enduring Material
Activity Release Date: October 15, 2022
Activity Expiration Date: November 14, 2023
Time to Complete Activity: 60 minutes

Activity Description

Eosinophilic esophagitis (EoE) is an increasingly prevalent, chronic, T2 inflammatory disease triggered by food and/or environmental allergens. Due to underlying tissue inflammation, patients suffer diminished quality of life due to symptoms such as weight loss, difficulty swallowing, and heartburn. Patients can experience these symptoms for a long time before receiving a proper diagnosis. Once diagnosed, treatment options have historically been limited. Fortunately, therapies that treat other type 2 disorders are in development or are approved to treat EoE. At a recent live event, experts used patient cases to discuss the diagnosis, underlying causes, and the newest treatments for EoE, including biologic therapies. Watch this on-demand version now!

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists (pediatric and adult), allergists/immunologists (pediatric and adult), specialty NPs and PAs, and other healthcare professionals involved in the care of patients with eosinophilic esophagitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Distinguish signs and symptoms of eosinophilic esophagitis (EoE) among children and adults to enable an earlier diagnosis and minimize complications due to uncontrolled disease
  • Recognize underlying mechanisms of EoE, including the role of key cytokines such as interleukins -4, -13, and -5 as drivers of type 2 inflammation and how this relates to emerging treatment
  • Apply the latest expert recommendations and clinical evidence to the treatment of patients with EoE, particularly as novel and emerging agents become available

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Faculty/Planner
Sandeep K. Gupta, MD
Medical Director for Research
Community Health Network
Professor of Clinical Pediatrics
Pediatric Gastroenterology/Hepatology/Nutrition
Riley Hospital for Children
Indiana University School of Medicine
Indianapolis, Indiana

Sandeep K. Gupta, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Adare Pharma Solutions; Celgene Corporation; Gossamer Bio, Inc.; QOL Medical, LLC; Takeda Pharmaceuticals U.S.A., Inc.; and ViaSkin.
Grant/Research Support from AstraZeneca; Ellodi Pharmaceuticals; and National Institutes of Health (NIH).

Faculty/Planner
Gregory M. Constantine, MD
Clinician-Scientist - Eosinophilic Disorders
Allergy/Immunology
Bethesda, Maryland

Gregory M. Constantine, MD, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Amanda B. Muir, MD
Attending Physician
Assistant Professor of Pediatrics
Department of Pediatrics
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Amanda B. Muir, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squib; Medtronic; and Nexstone Immunology.
Grant/Research Support from Morphic Therapeutic.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care

Media: Enduring Material
Activity Release Date: October 15, 2022
Activity Expiration Date: November 14, 2023
Time to Complete Activity: 60 minutes

Activity Description

Eosinophilic esophagitis (EoE) is an increasingly prevalent, chronic, T2 inflammatory disease triggered by food and/or environmental allergens. Due to underlying tissue inflammation, patients suffer diminished quality of life due to symptoms such as weight loss, difficulty swallowing, and heartburn. Patients can experience these symptoms for a long time before receiving a proper diagnosis. Once diagnosed, treatment options have historically been limited. Fortunately, therapies that treat other type 2 disorders are in development or are approved to treat EoE. At a recent live event, experts used patient cases to discuss the diagnosis, underlying causes, and the newest treatments for EoE, including biologic therapies. Watch this on-demand version now!

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists (pediatric and adult), allergists/immunologists (pediatric and adult), specialty NPs and PAs, and other healthcare professionals involved in the care of patients with eosinophilic esophagitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Distinguish signs and symptoms of eosinophilic esophagitis (EoE) among children and adults to enable an earlier diagnosis and minimize complications due to uncontrolled disease
  • Recognize underlying mechanisms of EoE, including the role of key cytokines such as interleukins -4, -13, and -5 as drivers of type 2 inflammation and how this relates to emerging treatment
  • Apply the latest expert recommendations and clinical evidence to the treatment of patients with EoE, particularly as novel and emerging agents become available

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Faculty/Planner
Sandeep K. Gupta, MD
Medical Director for Research
Community Health Network
Professor of Clinical Pediatrics
Pediatric Gastroenterology/Hepatology/Nutrition
Riley Hospital for Children
Indiana University School of Medicine
Indianapolis, Indiana

Sandeep K. Gupta, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Adare Pharma Solutions; Celgene Corporation; Gossamer Bio, Inc.; QOL Medical, LLC; Takeda Pharmaceuticals U.S.A., Inc.; and ViaSkin.
Grant/Research Support from AstraZeneca; Ellodi Pharmaceuticals; and National Institutes of Health (NIH).

Faculty/Planner
Gregory M. Constantine, MD
Clinician-Scientist - Eosinophilic Disorders
Allergy/Immunology
Bethesda, Maryland

Gregory M. Constantine, MD, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Amanda B. Muir, MD
Attending Physician
Assistant Professor of Pediatrics
Department of Pediatrics
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Amanda B. Muir, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squib; Medtronic; and Nexstone Immunology.
Grant/Research Support from Morphic Therapeutic.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

October 15, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

Start

Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

Media: Enduring Material
Activity Release Date: October 7, 2022
Activity Expiration Date: October 6, 2023
Time to Complete Activity: 60 minutes

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP.

In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration.

Target Audience

This activity has been designed to meet the educational needs of physicians, nurses, pharmacists, and other clinicians involved in the care of patients with nasal polyps.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy
  • Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders
  • Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Anju T. Peters, MD, MS
Professor of Medicine,
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Anju T. Peters, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; GlaxoSmithKline; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AstraZeneca; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.

Patient/Planner
Rhonda Nelson

Rhonda Nelson has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-039-H01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

Media: Enduring Material
Activity Release Date: October 7, 2022
Activity Expiration Date: October 6, 2023
Time to Complete Activity: 60 minutes

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP.

In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration.

Target Audience

This activity has been designed to meet the educational needs of physicians, nurses, pharmacists, and other clinicians involved in the care of patients with nasal polyps.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy
  • Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders
  • Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Anju T. Peters, MD, MS
Professor of Medicine,
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Anju T. Peters, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; GlaxoSmithKline; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AstraZeneca; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.

Patient/Planner
Rhonda Nelson

Rhonda Nelson has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-039-H01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

October 07, 2022
Credits: 1.0 CME / NCPD / CPE
University of Florida College of Medicine
A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes

A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes

Start

A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes


Activity Description and Educational Objectives

Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Traditionally used treatments for gMG are broadly immunosuppressive, do not target pathogenic immunoglobulin G (IgG) autoantibodies, and provide insufficient symptom relief with significant side effects. Fortunately, advances in the understanding of gMG pathogenesis are leading to the development of new treatment options, including neonatal Fc receptor (FcRn) modulators such as the recently approved efgartigimod, and rozanolixizumab, which recently completed phase 3 trials. As with all new and emerging therapeutics, it is important for clinicians to remain abreast of the latest data.

At a recent live event, a multidisciplinary panel of experts compared the safety, efficacy, and tolerability of new treatment options with traditional therapies for gMG. Audience members received expert advice from the perspective of a neurologist, pharmacist, and infusion nurse, with the goal of providing their patients with individualized care through FcRn modulation therapy.

Upon completion of this activity, participants should be better able to:

  • Compare safety, efficacy, and tolerability of new treatment options with traditional therapies for generalized myasthenia gravis (gMG)
  • Apply an understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
  • Implement a safe administration protocol for the use of FcRn-modulating therapy that includes infusion procedures, premedications, vaccinations, and treatment cycle timing

Target Audience

This activity has been designed to meet the educational needs of neurology specialists (neuromuscular, neuroimmunology, neuro-ophthalmology, and general neurology), nurse practitioners, physician assistants, infusion nurses, pharmacists, and other clinicians involved in the management of gMG.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: October 2, 2022 - November 1, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.

Chair & Presenter
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina
Chapel Hill, North Carolina

James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Toleranzia AB; and UCB Inc.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; argenx; Cartesian Therapeutics, Inc.; Centers for Disease Control and Prevention; Millennium Pharmaceuticals; National Institutes of Health; Patient-Centered Outcomes Research Institute; and UCB Inc.
Other Financial or Material Support in the form of Stock dividends from General Electric Company; GlaxoSmithKline; Johnson & Johnson Services, Inc.; and Pfizer.

Presenter
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing
Optum Infusion Pharmacy
Lenexa, Kansas

Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Evolve Biologics; Grifols, S.A.; Koru Pharmaceuticals Co., LTD.; Octapharma AG; Pfizer; and Takeda Pharmaceuticals U.S.A., Inc.

Presenter

Stephanie Iyer, PharmD, CPP, BCACP
Clinical Pharmacist Practitioner, UNC Neurology Clinic
UNC Healthcare
Department of Pharmacy
Chapel Hill, North Carolina

Stephanie Iyer, PharmD, CPP, BCACP, has no financial interests/relationships or affiliations in relation to this activity.

Accreditation, Credit, and Support

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an educational grant from argenx US, Inc.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and TBD contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-038-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the University of Florida College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the University of Florida College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes


Activity Description and Educational Objectives

Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Traditionally used treatments for gMG are broadly immunosuppressive, do not target pathogenic immunoglobulin G (IgG) autoantibodies, and provide insufficient symptom relief with significant side effects. Fortunately, advances in the understanding of gMG pathogenesis are leading to the development of new treatment options, including neonatal Fc receptor (FcRn) modulators such as the recently approved efgartigimod, and rozanolixizumab, which recently completed phase 3 trials. As with all new and emerging therapeutics, it is important for clinicians to remain abreast of the latest data.

At a recent live event, a multidisciplinary panel of experts compared the safety, efficacy, and tolerability of new treatment options with traditional therapies for gMG. Audience members received expert advice from the perspective of a neurologist, pharmacist, and infusion nurse, with the goal of providing their patients with individualized care through FcRn modulation therapy.

Upon completion of this activity, participants should be better able to:

  • Compare safety, efficacy, and tolerability of new treatment options with traditional therapies for generalized myasthenia gravis (gMG)
  • Apply an understanding of the rationale and mechanisms for reducing levels of autoreactive IgG antibodies using FcRn-modulating therapies when making gMG treatment decisions
  • Implement a safe administration protocol for the use of FcRn-modulating therapy that includes infusion procedures, premedications, vaccinations, and treatment cycle timing

Target Audience

This activity has been designed to meet the educational needs of neurology specialists (neuromuscular, neuroimmunology, neuro-ophthalmology, and general neurology), nurse practitioners, physician assistants, infusion nurses, pharmacists, and other clinicians involved in the management of gMG.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: October 2, 2022 - November 1, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.

Chair & Presenter
James F. Howard Jr., MD
Professor of Neurology, Medicine and Allied Health
Department of Neurology
The University of North Carolina
Chapel Hill, North Carolina

James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; argenx; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Regeneron Pharmaceuticals Inc.; sanofi-aventis U.S. LLC; Toleranzia AB; and UCB Inc.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; argenx; Cartesian Therapeutics, Inc.; Centers for Disease Control and Prevention; Millennium Pharmaceuticals; National Institutes of Health; Patient-Centered Outcomes Research Institute; and UCB Inc.
Other Financial or Material Support in the form of Stock dividends from General Electric Company; GlaxoSmithKline; Johnson & Johnson Services, Inc.; and Pfizer.

Presenter
Amy Clarke, MSN, RN, IgCN
Vice President
Clinical Nursing
Optum Infusion Pharmacy
Lenexa, Kansas

Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Evolve Biologics; Grifols, S.A.; Koru Pharmaceuticals Co., LTD.; Octapharma AG; Pfizer; and Takeda Pharmaceuticals U.S.A., Inc.

Presenter

Stephanie Iyer, PharmD, CPP, BCACP
Clinical Pharmacist Practitioner, UNC Neurology Clinic
UNC Healthcare
Department of Pharmacy
Chapel Hill, North Carolina

Stephanie Iyer, PharmD, CPP, BCACP, has no financial interests/relationships or affiliations in relation to this activity.

Accreditation, Credit, and Support

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an educational grant from argenx US, Inc.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and TBD contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-038-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the University of Florida College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the University of Florida College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

October 02, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Start

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with AML.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings
  • Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features
  • Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent medical education grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-102-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier Pharmaceuticals LLC; Shattuck Labs, Inc.; Syndax Pharmaceuticals, Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Fate Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; NovImmune SA; Pfizer Inc.; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research funding goes to institution.

Co-Chair/Planner
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir T. Fathi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; Amgen Inc.; Astellas Pharma Inc.; Blueprint Medicines Corporation; Celgene Corporation/Bristol Myers Squibb; EnClear Therapies; Foghorn Therapeutics; Forma Therapeutics; Genentech, Inc.; ImmunoGen, Inc.; Ipsen Pharma; Kite Pharma; Kura Oncology, Inc.; Mablytics; MorphoSys AG; Novartis Pharmaceuticals Corporation; Orum; PureTech Health; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; and Celgene Corporation/Bristol Myers Squibb.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with AML.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings
  • Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features
  • Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent medical education grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-102-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier Pharmaceuticals LLC; Shattuck Labs, Inc.; Syndax Pharmaceuticals, Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Fate Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; NovImmune SA; Pfizer Inc.; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research funding goes to institution.

Co-Chair/Planner
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir T. Fathi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; Amgen Inc.; Astellas Pharma Inc.; Blueprint Medicines Corporation; Celgene Corporation/Bristol Myers Squibb; EnClear Therapies; Foghorn Therapeutics; Forma Therapeutics; Genentech, Inc.; ImmunoGen, Inc.; Ipsen Pharma; Kite Pharma; Kura Oncology, Inc.; Mablytics; MorphoSys AG; Novartis Pharmaceuticals Corporation; Orum; PureTech Health; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; and Celgene Corporation/Bristol Myers Squibb.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 29, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Start

Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens
  • Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL
  • Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; and Merck & Co., Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-104-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Co-Chair/Planner
Deborah M. Stephens, DO
Associate Professor
Director for Lymphoid Malignancies Program
Division of Hematology and Hematologic Malignancies
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah

Deborah M. Stephens, DO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; CSL Behring; Celgene Corporation; Epizyme, Inc.; Genentech, Inc.; Lilly; and TG Therapeutics, Inc.
Grant/Research Support from Acerta Pharma; Juno Pharmaceuticals; MingSight Pharmaceuticals, Inc.; Newave Pharmaceutical Inc.; and Novartis Pharmaceuticals Corporation.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens
  • Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL
  • Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; and Merck & Co., Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-104-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Co-Chair/Planner
Deborah M. Stephens, DO
Associate Professor
Director for Lymphoid Malignancies Program
Division of Hematology and Hematologic Malignancies
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah

Deborah M. Stephens, DO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; CSL Behring; Celgene Corporation; Epizyme, Inc.; Genentech, Inc.; Lilly; and TG Therapeutics, Inc.
Grant/Research Support from Acerta Pharma; Juno Pharmaceuticals; MingSight Pharmaceuticals, Inc.; Newave Pharmaceutical Inc.; and Novartis Pharmaceuticals Corporation.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 29, 2022
Sagar Lonial, MD, FACP
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies

Start

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies


Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today to earn credit!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other clinicians involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the latest evidence supporting the treatment roles of novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T therapy, in relapsed/refractory disease
  • Develop evidence-based regimens with novel BCMA/ADCs, bispecifics, and cellular approaches that are informed by factors such as patient preference, disease prognosis, and functional status, among others
  • Manage practical aspects of BCMA-targeted therapy, including appropriate dosing/scheduling; patient counseling; and unique safety considerations, such as cytopenias, infusion-related events, ocular toxicity, and CRS, among others

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported through independent medical education grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-103-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies


Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today to earn credit!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other clinicians involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the latest evidence supporting the treatment roles of novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T therapy, in relapsed/refractory disease
  • Develop evidence-based regimens with novel BCMA/ADCs, bispecifics, and cellular approaches that are informed by factors such as patient preference, disease prognosis, and functional status, among others
  • Manage practical aspects of BCMA-targeted therapy, including appropriate dosing/scheduling; patient counseling; and unique safety considerations, such as cytopenias, infusion-related events, ocular toxicity, and CRS, among others

Accreditation, Support, and Credit

JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported through independent medical education grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-103-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 29, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

Start

The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

Media: Enduring Material
Activity Release Date: September 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of MDS.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS
  • Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS
  • Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS
  • Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-100-H01-P
Type of Activity: Knowledge

Faculty Disclosures

Co-Chair/Planner
Guillermo Garcia-Manero, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Gail J. Roboz, MD
Professor of Medicine
Director of the Clinical and Translational Leukemia Programs
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

Gail J. Roboz, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Janssen Pharmaceuticals, Inc.
Other Financial or Material Support as Consultant or Advisory Board or Data and Safety Monitoring Committee for AbbVie; Agios Pharmaceuticals Inc.; Amgen Inc.; AstraZeneca; Astellas Pharma US, Inc.; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb; Catamaran; Celgene Corporation; F. Hoffmann-La Roche AG; GlaxoSmithKline; Helsinn Healthcare; Janssen Pharmaceuticals, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Mesoblast Ltd; Novartis Pharmaceuticals Corporation; Pfizer; Syndax Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited-IRC Chair.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

Media: Enduring Material
Activity Release Date: September 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians (including hematology-oncology NPs and PAs), and other clinicians involved in the management of MDS.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS
  • Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS
  • Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS
  • Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-100-H01-P
Type of Activity: Knowledge

Faculty Disclosures

Co-Chair/Planner
Guillermo Garcia-Manero, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Guillermo Garcia-Manero, MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Gail J. Roboz, MD
Professor of Medicine
Director of the Clinical and Translational Leukemia Programs
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

Gail J. Roboz, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Janssen Pharmaceuticals, Inc.
Other Financial or Material Support as Consultant or Advisory Board or Data and Safety Monitoring Committee for AbbVie; Agios Pharmaceuticals Inc.; Amgen Inc.; AstraZeneca; Astellas Pharma US, Inc.; bluebird bio, Inc.; Blueprint Medicines; Bristol Myers Squibb; Catamaran; Celgene Corporation; F. Hoffmann-La Roche AG; GlaxoSmithKline; Helsinn Healthcare; Janssen Pharmaceuticals, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Mesoblast Ltd; Novartis Pharmaceuticals Corporation; Pfizer; Syndax Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited-IRC Chair.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 27, 2022
Sonia Glennie, ARNP MSN OCN AGPCNP-BC
Credits: 0.5 NCPD / ILNA
PVI, PeerView Institute for Medical Education
Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

Start

Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

Media: Enduring Material
Activity Release Date: September 14, 2022
Activity Expiration Date: September 13, 2023
Time to Complete Activity: 30 minutes

Activity Description

Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, and other clinicians involved in the care of patients with DLBCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL)
  • Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting
  • Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity
  • Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Sonia Glennie, ARNP MSN OCN AGPCNP-BC
Nurse Practitioner
Hematology/Oncology
Swedish Cancer Institute
Seattle, Washington

Sonia Glennie, ARNP MSN OCN AGPCNP-BC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb/Celgene Corporation; Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.

Faculty/Planner
Amy Goodrich, CRNP
Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Amy Goodrich, CRNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc; AstraZeneca; BeiGene; Fresenius Kabi; Genentech, Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from ADC Therapeutics America, Inc., Incyte Corporation, and MorphoSys US Inc.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
0.50 point: Care Continuum, Care of the Pediatric Hematology and Oncology Patient, Cellular Collection, Preparative Regimens, and Infusion, Disease-Related Biology, Early Post-Transplant Management, Foundations of Transplant, Late Post-Transplant Management, Oncologic Emergencies, Oncology Nursing Practice, Professional Practice/Performance, Symptom Management, Palliative Care, Supportive Care, Transplant Process and Infusion, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies

Media: Enduring Material
Activity Release Date: September 14, 2022
Activity Expiration Date: September 13, 2023
Time to Complete Activity: 30 minutes

Activity Description

Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, and other clinicians involved in the care of patients with DLBCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL)
  • Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting
  • Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity
  • Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Sonia Glennie, ARNP MSN OCN AGPCNP-BC
Nurse Practitioner
Hematology/Oncology
Swedish Cancer Institute
Seattle, Washington

Sonia Glennie, ARNP MSN OCN AGPCNP-BC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb/Celgene Corporation; Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.

Faculty/Planner
Amy Goodrich, CRNP
Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Amy Goodrich, CRNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc; AstraZeneca; BeiGene; Fresenius Kabi; Genentech, Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from ADC Therapeutics America, Inc., Incyte Corporation, and MorphoSys US Inc.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
0.50 point: Care Continuum, Care of the Pediatric Hematology and Oncology Patient, Cellular Collection, Preparative Regimens, and Infusion, Disease-Related Biology, Early Post-Transplant Management, Foundations of Transplant, Late Post-Transplant Management, Oncologic Emergencies, Oncology Nursing Practice, Professional Practice/Performance, Symptom Management, Palliative Care, Supportive Care, Transplant Process and Infusion, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 14, 2022
Credits: 1.0 CME / NCPD / CPE
AGA Institute
An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

Start

An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

Activity Description and Educational Objectives

In this animated activity, Dr. Brooks D. Cash shares expert guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC, highlighting key differential diagnoses to rule out and alarm features that warrant further investigation.

You will be able to translate the latest clinical findings related to current over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as well as gain insight into the clinical use of newer/novel treatment options.

Dr. Cash also shares effective communication strategies you can use with your patients to increase their participation in their care and maximize their treatment satisfaction.

Upon completion of this activity, participants should be better able to:

  • Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC
  • Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents
  • Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, obstetricians, gynecologists, nurses, NPs, PAs, pharmacists, and other clinicians involved in the care of patients with irritable bowel syndrome.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: September 12, 2022 - September 11, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The American Gastroenterological Association (AGA) Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.

Chair
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from AbbVie Inc.; Ardelyx; QOL Medical, LLC; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau participant with Salix Pharmaceuticals.

Patient Advocate
Johannah Ruddy, MEd

Johannah Ruddy, MEd, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Mahana Therapeutics, Inc.
Speaker for AbbVie Inc.; Mahana Therapeutics, Inc.; and Salix/Bausch Health Companies Inc.
Other Financial or Material Support as an independent contractor for Salix/Bausch Health Companies Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The AGA Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an independent educational grant from AbbVie and Ironwood Pharmaceuticals.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-032-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer's product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the AGA Institute are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the AGA Institute.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief

Activity Description and Educational Objectives

In this animated activity, Dr. Brooks D. Cash shares expert guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC, highlighting key differential diagnoses to rule out and alarm features that warrant further investigation.

You will be able to translate the latest clinical findings related to current over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as well as gain insight into the clinical use of newer/novel treatment options.

Dr. Cash also shares effective communication strategies you can use with your patients to increase their participation in their care and maximize their treatment satisfaction.

Upon completion of this activity, participants should be better able to:

  • Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC
  • Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents
  • Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, obstetricians, gynecologists, nurses, NPs, PAs, pharmacists, and other clinicians involved in the care of patients with irritable bowel syndrome.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: September 12, 2022 - September 11, 2023
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The American Gastroenterological Association (AGA) Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.

Chair
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from AbbVie Inc.; Ardelyx; QOL Medical, LLC; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau participant with Salix Pharmaceuticals.

Patient Advocate
Johannah Ruddy, MEd

Johannah Ruddy, MEd, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Mahana Therapeutics, Inc.
Speaker for AbbVie Inc.; Mahana Therapeutics, Inc.; and Salix/Bausch Health Companies Inc.
Other Financial or Material Support as an independent contractor for Salix/Bausch Health Companies Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The AGA Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an independent educational grant from AbbVie and Ironwood Pharmaceuticals.

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-032-H01-P
Type of Activity: Knowledge

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer's product labeling.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and the AGA Institute are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and the AGA Institute.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 12, 2022
Credits: 1.0 CME / MOC / NCPD
Medical Learning Institute, Inc.
Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

Start

Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: September 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC.

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions
  • Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy
  • Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC
  • Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Genentech, a member of the Roche Group, Lilly, and Turning Point Therapeutics, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Faculty Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX, Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos, Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics; Medendi Inc.; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare Therapeutics; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Touch Medical Media; Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: September 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC.

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions
  • Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy
  • Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC
  • Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences

Accreditation, Support, and Credit


JAP In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Genentech, a member of the Roche Group, Lilly, and Turning Point Therapeutics, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Faculty Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX, Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos, Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics; Medendi Inc.; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare Therapeutics; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Touch Medical Media; Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 02, 2022
Credits: 1.0 CME / MOC / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

Start

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease


Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: October 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, oncology nurses, pharmacists, and other clinicians involved in the management of patients with MCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings
  • Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease
  • Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; Loxo Oncology, Inc.; and Secura Bio.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie Inc.; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; and Loxo Oncology, Inc.

Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

Nirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Epizyme, Inc.; Incyte Corporation; Kite; Lilly; Novartis Pharmaceuticals Corporation; Miltenyi Biotec; and TG Therapeutics, Inc.
Grant/Research Support from Miltenyi Biotec.
Speaker for Incyte Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-041-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease


Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: October 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, NPs, PAs, oncology nurses, pharmacists, and other clinicians involved in the management of patients with MCL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings
  • Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease
  • Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Haematology Consultant
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; Loxo Oncology, Inc.; and Secura Bio.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie Inc.; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite; Lilly; and Loxo Oncology, Inc.

Co-Chair/Planner
Nirav Shah, MD, MS
Associate Professor of Medicine
Division of Hematology and Oncology
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

Nirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Epizyme, Inc.; Incyte Corporation; Kite; Lilly; Novartis Pharmaceuticals Corporation; Miltenyi Biotec; and TG Therapeutics, Inc.
Grant/Research Support from Miltenyi Biotec.
Speaker for Incyte Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-041-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

September 02, 2022
Credits: 0.5 CME / MOC / NCPD / IPCE
PVI, PeerView Institute for Medical Education
Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

Start

Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

Expert commentary is based on data presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Media: Enduring Material
Activity Release Date: August 30, 2022
Activity Expiration Date: August 29, 2023
Time to Complete Activity: 30 minutes

Activity Description

In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC.

Target Audience

This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with endometrial cancer

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC
  • Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences
  • Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Ritu Salani, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Instil Bio; Merck & Co., Inc.; Mersana Therapeutics; Regeneron Pharmaceuticals; and Seagen Inc.
Grant/Research Support from Genentech.

Faculty/Planner
Rachel Frankenthal, MMS, PA-C, MPH
Physician Assistant
Division of Gynecologic Oncology
UCLA Medical Center
Los Angeles, California

Rachel Frankenthal, MMS, PA-C, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ImmunoGen, Inc.
Speaker for Horizon CME and PCE Oncology Conference.

Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

Expert commentary is based on data presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Media: Enduring Material
Activity Release Date: August 30, 2022
Activity Expiration Date: August 29, 2023
Time to Complete Activity: 30 minutes

Activity Description

In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC.

Target Audience

This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with endometrial cancer

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC
  • Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences
  • Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Ritu Salani, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Instil Bio; Merck & Co., Inc.; Mersana Therapeutics; Regeneron Pharmaceuticals; and Seagen Inc.
Grant/Research Support from Genentech.

Faculty/Planner
Rachel Frankenthal, MMS, PA-C, MPH
Physician Assistant
Division of Gynecologic Oncology
UCLA Medical Center
Los Angeles, California

Rachel Frankenthal, MMS, PA-C, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ImmunoGen, Inc.
Speaker for Horizon CME and PCE Oncology Conference.

Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 30, 2022
Credits: 0.5 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

Start

A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

Media: Enduring Material
Activity Release Date: August 26, 2022
Activity Expiration Date: August 25, 2023
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures.

Target Audience

This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease specialists, and other HIV prevention workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19
  • Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures
  • Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Rupa R. Patel, MD, MPH, DTM&H
PrEP Physician and Researcher
Research Associate Professor (Voluntary)
Division of Infectious Diseases
Washington University
St. Louis, Missouri

Rupa R. Patel, MD, MPH, DTM&H, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with ViiV Healthcare.

Patient Advocate/Planner
Faith Mitchell, MPH
HIV Prevention Specialist
CDC Let’s Stop HIV Together
Campaign Ambassador
Adjunct Professor, Health Services
Trinity Washington University
Washington, DC

Faith Mitchell, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


 

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-037-H02-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care

Media: Enduring Material
Activity Release Date: August 26, 2022
Activity Expiration Date: August 25, 2023
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures.

Target Audience

This activity has been designed to meet the educational needs of primary care providers, HIV care providers, infectious disease specialists, and other HIV prevention workforce professionals (nurses, pharmacists, social workers, case managers, certified health educators, and community health workers).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19
  • Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures
  • Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Rupa R. Patel, MD, MPH, DTM&H
PrEP Physician and Researcher
Research Associate Professor (Voluntary)
Division of Infectious Diseases
Washington University
St. Louis, Missouri

Rupa R. Patel, MD, MPH, DTM&H, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with ViiV Healthcare.

Patient Advocate/Planner
Faith Mitchell, MPH
HIV Prevention Specialist
CDC Let’s Stop HIV Together
Campaign Ambassador
Adjunct Professor, Health Services
Trinity Washington University
Washington, DC

Faith Mitchell, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


 

JAP In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-22-037-H02-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 26, 2022
Credits: 1.0 CME / MOC / NCPD / CPE / IPCE
PVI, PeerView Institute for Medical Education
Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

Start

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?


Media: Enduring Material
Activity Release Date: August 18, 2022
Activity Expiration Date: August 17, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis.

Target Audience

This activity has been designed to meet the educational needs of pediatricians, pediatric specialists in dermatology and allergy/immunology, primary care physicians, NPs, PAs, nurses, pharmacists, and other clinicians involved in the management of patients with atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD)
  • Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD
  • Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD
  • Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD
  • Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for LEO Pharma Inc.
Grant/Research Support from Galderma Laboratories, L.P.; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Speakers Bureau participant with Beiersdorf, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABP MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-033-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?


Media: Enduring Material
Activity Release Date: August 18, 2022
Activity Expiration Date: August 17, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis.

Target Audience

This activity has been designed to meet the educational needs of pediatricians, pediatric specialists in dermatology and allergy/immunology, primary care physicians, NPs, PAs, nurses, pharmacists, and other clinicians involved in the management of patients with atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD)
  • Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD
  • Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD
  • Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD
  • Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for LEO Pharma Inc.
Grant/Research Support from Galderma Laboratories, L.P.; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Speakers Bureau participant with Beiersdorf, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABP MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-033-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

IPCE This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 18, 2022
Credits: 1.0 CME / MOC / NCPD / ILNA
PVI, PeerView Institute for Medical Education
Uncovering Gene Fusions & Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment

Uncovering Gene Fusions & Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment

Start

Uncovering Gene Fusions & Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment

Media: Enduring Material
Activity Release Date: August 16, 2022
Activity Expiration Date: September 15, 2023
Time to Complete Activity: 60 minutes

Activity Description

Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific tumor types (such as RET alterations in lung and thyroid cancers). These newer therapies have demonstrated impressive efficacy with favorable safety profiles, and their use can significantly improve patient outcomes and quality of life. The tumor-agnostic indications are anticipated to expand further, and novel options are also emerging for patients who have developed resistance to standard RET- and TRK-targeted therapies.

In this PeerView educational offering, experts on gene fusion-positive solid tumors provide a cutting-edge update on the role and relevance of gene fusions and other key alterations in solid tumors. These KOLs offer guidance on how to best identify patients with gene alterations and discuss accumulating clinical evidence for the best use of targeted therapies, while also providing practical guidance for optimizing multidisciplinary and interprofessional strategies for biomarker testing and use of targeted therapy across solid tumors harboring NTRK and RET fusions and other actionable alterations.

Target Audience

This activity has been designed to meet the educational needs of medical and clinical oncologists, pathologists, molecular pathologists, advanced practice providers, nurses, and other clinicians involved in the management of patients with solid tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the role of NTRK, RET, ALK, and other key genomic alterations in the oncogenesis of solid tumors, the importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes
  • Collaborate with the broader cancer care team to identify patients for biomarker testing, select appropriate tests to capture all relevant genomic alterations, including gene fusions, and interpret testing results to guide treatment selection
  • Apply the latest evidence and guidelines to individualize targeted therapy for patients with cancers harboring NTRK, RET, ALK, and other targetable genomic alterations
  • Educate patients about the role of biomarker testing, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX, Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos, Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics; Medendi Inc.; Monopteros Therapeutics; Merus; Monte Rosa Therapeutics; MORE Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare Therapeutics; Touch Medical Media; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

Faculty/Planner
George D. Demetri, MD
Senior Vice President for Experimental Therapeutics
Dana-Farber Cancer Institute
Co-Director, Ludwig Center at Harvard
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

George D. Demetri, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acrivon Therapeutics; Bessor Pharma; Caris Life Sciences; CellCarta; C4 Therapeutics, Inc.; EMD Serono; Erasca, Inc.; G1 Therapeutics; GlaxoSmithKline; ICON plc; Ikena Oncology; ImmuneID, Inc.; Kojin Therapeutics, Inc.; Mirati Therapeutics, Inc.; Rain Therapeutics; Relay Therapeutics; Sanofi; and Synlogic.
Grant/Research Support from Adaptimmune Therapeutics plc; Bayer Corporation; Daiichi Sankyo; GlaxoSmithKline; Janssen; Novartis Pharmaceuticals Corporation; PharmaMar; Pfizer; and Roche/Genentech.
Other Financial or Material Support Board of Directors/Advisory Board Consultant for Blueprint Medicines.

Faculty/Planner
Vivek Subbiah, MD
Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Executive Medical Director
Department of Medical Oncology Research
MD Anderson Cancer Center Network
Houston, Texas

Vivek Subbiah, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Daiichi Sankyo, Inc.; Helsinn Pharmaceuticals; Incyte; Lilly; Loxo Oncology; MedImmune; Novartis Pharmaceuticals Corporation; Pfizer; QED Pharma; Relay Therapeutics; Roche/Genentech; and Signant Health.
Grant/Research Support from AbbVie; Agensys Inc.; Alfasigma USA, Inc.; Altum Pharmaceuticals, Inc.; Amgen Inc.; Bayer Corporation; Berg LLC; Blueprint Medicines; Boston Biomedical, Inc.; Boston Pharmaceuticals; Celgene; D3 Pharma; Dragonfly Therapeutics; Exelixis; FUJIFILM Pharmaceuticals U.S.A., Inc.; GlaxoSmithKline; Helsinn Pharmaceuticals; Idera; Incyte; Inhibrx, Inc.; Lilly; Loxo Oncology; MedImmune; MultiVir, Inc.; NanoCarrier Co., Ltd.; Northwest Biotherapeutics; Novartis Pharmaceuticals Corporation; Pfizer; PharmaMar; Roche/Genentech; Takeda; Turning Point Therapeutics; and Vegenics.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Uncovering Gene Fusions & Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment

Media: Enduring Material
Activity Release Date: August 16, 2022
Activity Expiration Date: September 15, 2023
Time to Complete Activity: 60 minutes

Activity Description

Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific tumor types (such as RET alterations in lung and thyroid cancers). These newer therapies have demonstrated impressive efficacy with favorable safety profiles, and their use can significantly improve patient outcomes and quality of life. The tumor-agnostic indications are anticipated to expand further, and novel options are also emerging for patients who have developed resistance to standard RET- and TRK-targeted therapies.

In this PeerView educational offering, experts on gene fusion-positive solid tumors provide a cutting-edge update on the role and relevance of gene fusions and other key alterations in solid tumors. These KOLs offer guidance on how to best identify patients with gene alterations and discuss accumulating clinical evidence for the best use of targeted therapies, while also providing practical guidance for optimizing multidisciplinary and interprofessional strategies for biomarker testing and use of targeted therapy across solid tumors harboring NTRK and RET fusions and other actionable alterations.

Target Audience

This activity has been designed to meet the educational needs of medical and clinical oncologists, pathologists, molecular pathologists, advanced practice providers, nurses, and other clinicians involved in the management of patients with solid tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the role of NTRK, RET, ALK, and other key genomic alterations in the oncogenesis of solid tumors, the importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes
  • Collaborate with the broader cancer care team to identify patients for biomarker testing, select appropriate tests to capture all relevant genomic alterations, including gene fusions, and interpret testing results to guide treatment selection
  • Apply the latest evidence and guidelines to individualize targeted therapy for patients with cancers harboring NTRK, RET, ALK, and other targetable genomic alterations
  • Educate patients about the role of biomarker testing, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX, Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos, Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics; Medendi Inc.; Monopteros Therapeutics; Merus; Monte Rosa Therapeutics; MORE Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare Therapeutics; Touch Medical Media; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

Faculty/Planner
George D. Demetri, MD
Senior Vice President for Experimental Therapeutics
Dana-Farber Cancer Institute
Co-Director, Ludwig Center at Harvard
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

George D. Demetri, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acrivon Therapeutics; Bessor Pharma; Caris Life Sciences; CellCarta; C4 Therapeutics, Inc.; EMD Serono; Erasca, Inc.; G1 Therapeutics; GlaxoSmithKline; ICON plc; Ikena Oncology; ImmuneID, Inc.; Kojin Therapeutics, Inc.; Mirati Therapeutics, Inc.; Rain Therapeutics; Relay Therapeutics; Sanofi; and Synlogic.
Grant/Research Support from Adaptimmune Therapeutics plc; Bayer Corporation; Daiichi Sankyo; GlaxoSmithKline; Janssen; Novartis Pharmaceuticals Corporation; PharmaMar; Pfizer; and Roche/Genentech.
Other Financial or Material Support Board of Directors/Advisory Board Consultant for Blueprint Medicines.

Faculty/Planner
Vivek Subbiah, MD
Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Executive Medical Director
Department of Medical Oncology Research
MD Anderson Cancer Center Network
Houston, Texas

Vivek Subbiah, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Daiichi Sankyo, Inc.; Helsinn Pharmaceuticals; Incyte; Lilly; Loxo Oncology; MedImmune; Novartis Pharmaceuticals Corporation; Pfizer; QED Pharma; Relay Therapeutics; Roche/Genentech; and Signant Health.
Grant/Research Support from AbbVie; Agensys Inc.; Alfasigma USA, Inc.; Altum Pharmaceuticals, Inc.; Amgen Inc.; Bayer Corporation; Berg LLC; Blueprint Medicines; Boston Biomedical, Inc.; Boston Pharmaceuticals; Celgene; D3 Pharma; Dragonfly Therapeutics; Exelixis; FUJIFILM Pharmaceuticals U.S.A., Inc.; GlaxoSmithKline; Helsinn Pharmaceuticals; Idera; Incyte; Inhibrx, Inc.; Lilly; Loxo Oncology; MedImmune; MultiVir, Inc.; NanoCarrier Co., Ltd.; Northwest Biotherapeutics; Novartis Pharmaceuticals Corporation; Pfizer; PharmaMar; Roche/Genentech; Takeda; Turning Point Therapeutics; and Vegenics.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit


JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 16, 2022
Credits: 0.5 NCPD
PVI, PeerView Institute for Medical Education
Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

Start

Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

Media: Enduring Material
Activity Release Date: August 11, 2022
Activity Expiration Date: August 10, 2023
Time to Complete Activity: 30 minutes

Activity Description

This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners, and nurse navigators.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy
  • Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity
  • Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN
Adult Nurse Practitioner
Department of Hematologic Oncology and Blood Disorders
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Tiffany A. Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
MD Anderson Cancer Center
Department of Lymphoma/Myeloma
Houston, Texas

Tiffany A. Richards, PhD, ANP-BC, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Legend Biotech; Sanofi; and Takeda.

Faculty/Planner
Donna D. Catamero, ANP-BC, OCN, CCRC
Associate Director, Myeloma Translational Research
The Mount Sinai Health System
New York, New York

Donna D. Catamero, ANP-BC, OCN, CCRC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Legend Biotech.
Grant/Research Support from GlaxoSmithKline.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Karyopharm Therapeutics.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action

Media: Enduring Material
Activity Release Date: August 11, 2022
Activity Expiration Date: August 10, 2023
Time to Complete Activity: 30 minutes

Activity Description

This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners, and nurse navigators.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy
  • Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity
  • Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN
Adult Nurse Practitioner
Department of Hematologic Oncology and Blood Disorders
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Tiffany A. Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
MD Anderson Cancer Center
Department of Lymphoma/Myeloma
Houston, Texas

Tiffany A. Richards, PhD, ANP-BC, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Legend Biotech; Sanofi; and Takeda.

Faculty/Planner
Donna D. Catamero, ANP-BC, OCN, CCRC
Associate Director, Myeloma Translational Research
The Mount Sinai Health System
New York, New York

Donna D. Catamero, ANP-BC, OCN, CCRC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Legend Biotech.
Grant/Research Support from GlaxoSmithKline.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

JAP In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Karyopharm Therapeutics.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

August 11, 2022

Pages